Cargando…
Identification of Mubritinib (TAK 165) as an inhibitor of KSHV driven primary effusion lymphoma via disruption of mitochondrial OXPHOS metabolism
KSHV-associated cancers have poor prognoses and lack therapeutics that selectively target viral gene functions. We developed a screening campaign to identify known drugs that could be repurposed for the treatment of KSHV-associated cancers. We focused on primary effusion lymphoma (PEL), which has pa...
Autores principales: | Calderon, Abram, Soldan, Samantha S., De Leo, Alessandra, Deng, Zhong, Frase, Drew M., Anderson, Emma M., Zhang, Yue, Vladimirova, Olga, Lu, Fang, Leung, Jessica C., Murphy, Maureen E., Lieberman, Paul M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679036/ https://www.ncbi.nlm.nih.gov/pubmed/33245718 http://dx.doi.org/10.18632/oncotarget.27815 |
Ejemplares similares
-
Mubritinib enhanced the inhibiting function of cisplatin in lung cancer by interfering with mitochondrial function
por: Dong, Jingyao, et al.
Publicado: (2022) -
LANA oligomeric architecture is essential for KSHV nuclear body formation and viral genome maintenance during latency
por: De Leo, Alessandra, et al.
Publicado: (2019) -
BET-Inhibitors Disrupt Rad21-Dependent Conformational Control of KSHV Latency
por: Chen, Horng-Shen, et al.
Publicado: (2017) -
Phase separation and DAXX redistribution contribute to LANA nuclear body and KSHV genome dynamics during latency and reactivation
por: Vladimirova, Olga, et al.
Publicado: (2021) -
Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors
por: Tolani, Bhairavi, et al.
Publicado: (2013)